ZD6474, a new treatment strategy for human osteosarcoma, and its potential synergistic effect with celecoxib

ZD6474, a small molecule VEGFR and EGFR tyrosine kinase inhibitor, has been considered as a promising tumor-targeted drug in various malignancies. EGFR and cyclooxygenase-2 (COX-2) were found overexpressed in osteosarcoma in previous reports, so here we tried to explore the anti-osteosarcoma effect...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:Oncotarget
Κύριοι συγγραφείς: Liu, Jiani, Wu, Jiangxue, Zhou, Ling, Pan, Changchuan, Zhou, Yi, Du, Wuying, Chen, Jie-min, Zhu, Xiaofeng, Shen, Jingnan, Chen, Shuai, Liu, Ran-yi, Huang, Wenlin
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: Impact Journals LLC 2015
Θέματα:
Research Paper
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4673269/
https://ncbi.nlm.nih.gov/pubmed/26050198
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια